CCM
FOLD

Cadian Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Cadian Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,389,344
Closed -$13.5M – 30
2019
Q4 		$13.5M Buy
1,389,344
+389,344
+39% +$3.56M 0.6% 26
2019
Q3 		$8.02M Buy
1,000,000
+400,000
+67% +$4.34M 0.38% 23
2019
Q2 		$7.49M Buy
600,000
+400,000
+200% +$5.08M 0.34% 25
2019
Q1 		$2.72M Buy
+200,000
New +$2.44M 0.11% 31
2017
Q4 		– Sell
-400,000
Closed -$6.03M – 32
2017
Q3 		$6.03M Buy
+400,000
New +$5.29M 0.28% 39

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Cadian Capital Management's FOLD Position: Q1 2020 in Review

Cadian Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 1,389,344 shares — an estimated $13.5M sold.

Cadian Capital Management first reported a position in FOLD in Q3 2017 and held it in 5 quarters. The position peaked at $13.5M in Q4 2019. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Cadian Capital Management reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Cadian Capital Management sold 1,389,344 Amicus Therapeutics shares in Q1 2020, an estimated $13.5M.
  • Cadian Capital Management first reported a position in Amicus Therapeutics in Q3 2017 and held it in 5 quarters.
  • Cadian Capital Management's Amicus Therapeutics position peaked at $13.5M in Q4 2019.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Cadian Capital Management's 13F filing for Q1 2020, filed 14 May 2020.